ArticleAmerican journal of nephrology2026

Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy.

Huixian Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.